Business Wire

ONERA-HEALTH

Share
Onera raises over €30M in Series C funding

Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round. This latest funding round brings Onera’s total investment to date to more than €55 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240115279169/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ruben de Francisco, Founder and CEO of Onera Health. (Photo: Business Wire)

The round was led by new investor EQT Life Sciences, investing from its EQT Health Economics 3 fund, co-led by new investor Gimv, and joined by existing investors, including Innovation Industries, Invest-NL, imec.xpand, BOM, and 15th Rock.

This strong backing will allow the company to accelerate manufacturing and deployment plans to meet the growing customer demand for its innovative, self-applied, no-wire end-to-end solution. Furthermore, the company intends to use the funds to expedite the clearance of the second generation of its polysomnography (PSG) system in Europe and the United States, further underlining the ambition to position itself as a leader in home PSG (hPSG) within the field of sleep medicine.

We are delighted that two premier Life Sciences investors, as well as our existing world-class investors, have the confidence to join and support us in the next phase of our company journey,” said Ruben de Francisco, Founder and CEO of Onera Health. “This capital infusion will accelerate our ability to scale in the US and Europe. We will continue aggressively investing in R&D, customer success, and geographic expansion to help the medical field provide the much-needed answers for millions of people affected by sleep disorders. We are incredibly proud and humbled by our success to date and look forward to driving growth together with our new partners.”

Drew Burdon, Partner at EQT Life Sciences, said: “Onera Health, with its disruptive medical technology, is a perfect fit for the EQT Health Economics strategy. We are dedicated to growing companies with the potential to have a meaningful impact on society, and Onera is strongly aligned with this mission. The company demonstrated a very strong product-market fit with great potential to improve the quality of patient care while also positively impacting the cost of healthcare. We could not be more thrilled to be supporting the next phase of their journey.”

“Gimv’s Life Sciences' partnership with Onera Health is driven by the shared commitment to addressing unmet clinical needs. Onera is perfectly positioned to support the continued growth potential of hospital-quality care at the patient’s home through its innovative sleep diagnostic solution. With its top-notch team and innovative patch-based technology, we believe Onera can and will democratize the gold-standard in sleep medicine,” Michaël Vlemmix, Partner at Gimv Life Sciences.

Onera Health focuses on breakthrough sleep testing solutions that are quick, convenient, and clinically accurate. The user-centric technology of their PSG system brings clinical-grade PSG diagnostics and monitoring directly to the patient’s bed— in the comfort of their own home. The MedTech and Digital Health company operates in the U.S., the Benelux, and the DACH region.

As part of this transaction, Drew Burdon and Michaël Vlemmix will join Onera Health’s Board of Directors.

Next month, Onera Health will showcase its product and discuss its impact at the AASM (American Academy of Sleep Medicine) event ‘Sleep Medicine Trends 2024’ on Feb. 23–24 in La Jolla, California.

About Onera

Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. For more information, go to onerahealth.com

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek. For more information, go to eqtgroup.com/private-capital/life-sciences/

About Gimv

Gimv is a European investment company listed on Euronext Brussels. With over 40 years of experience in private equity, Gimv currently has EUR 1.6 billion of assets under management. The portfolio has around 60 companies, with a combined turnover of EUR 3.7 billion and 20,000 employees.

As a recognised market leader in selected investment platforms, Gimv identifies entrepreneurial, innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv's five investment platforms are Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. In Life Sciences, Gimv focuses on European R&D-focused companies developing breakthrough solutions that have a positive impact on human health, from early preclinical proof of concept through to late-stage clinical trials. For more information, go to gimv.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240115279169/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Board Unveils New Foresight and Signals Products: Revolutionizing Business Planning with AI and Economic Intelligence19.2.2025 15:00:00 CET | Press release

Board, the leading Enterprise Planning Platform, is transforming the way businesses anticipate and adapt to economic shifts with today’s announcement of Board Foresight and Board Signals. These cutting-edge solutions, developed as a result of Board’s recent acquisition of Prevedere, empower enterprises with real-time economic indicators, predictive analytics, and the expertise of Board’s in-house economists—all backed by exclusive access to over 5 million global datasets. This release marks a huge step forward in completing Board’s product vision. By harnessing the power of macroeconomic intelligence, the Board Enterprise Planning Platform now enables more comprehensive, collaborative, and continuous planning capabilities than ever before. Board Foresight and Signals give business leaders the ability to look beyond internal historical data, forecast with greater accuracy, scenario plan with more agility, and make strategic decisions with confidence in an increasingly volatile world. Bo

PPG, PPG Foundation invested $18.4 million in communities worldwide in 202419.2.2025 15:00:00 CET | Press release

PPG (NYSE:PPG) and the PPG Foundation today announced that they invested $18.4 million worldwide in 2024, an increase of $900,000 over 2023. The 2024 funding supported more than 400 community partners and programs that focus on advancing education and delivering community sustainability while encouraging PPG employee volunteerism. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219834296/en/ PPG and the PPG Foundation invested $18.4 million worldwide in 2024 to programs that focus on advancing education and delivering community sustainability while encouraging PPG employee volunteerism. (Photo: Business Wire) “Around the world, PPG’s 2024 community engagement investments aimed to inspire students and aspiring STEM leaders, beautify neighborhoods and give our employees meaningful ways to give back,” said Malesia Dunn, executive director, PPG Foundation and corporate global social responsibility. “We’re focused on creating b

HSBC Continental Europe: 2024 Annual and Second Half Results19.2.2025 14:40:00 CET | Press release

Regulatory News: On 18 February 2025, HSBC Continental Europe’s Board of Directors reviewed the second half year results and approved the consolidated financial statements for 2024. At HSBC, our ambition is to be the preferred and most trusted international financial partner for our clients. In Continental Europe, we are focused on serving corporate and institutional clients, with a particular focus on connecting them to international markets, financing and facilitating trade within Europe and between Europe and the rest of the world. We also serve international high and ultra-high net worth clients of the HSBC Group through our private banking business in Luxembourg. In the second half of 2024, we accelerated our strategy by signing an agreement to sell our private banking business in Germany and a Memorandum of Understanding for the potential sale of our life insurance business in France1. Our results in 2024 reflected growth in wholesale transaction banking and financing, offset by

Parse Biosciences Launches 5 Million Cell Evercode WT Penta Kit for Single Cell Sequencing19.2.2025 14:15:00 CET | Press release

The most scalable and high-resolution single cell solution available Parse Biosciences, the leader in high-throughput single cell sequencing, today announced the launch of Evercode™ WT Penta and Penta 384, the first single cell RNA sequencing kits to profile 5 million cells and 384 samples in a single run. Evercode Penta and Penta 384 will begin shipping to customers the week of March 17. Scaling up single cell experiments—processing millions of cells instead of thousands—has revolutionized the way researchers study development, disease, and cellular heterogeneity. In 2021, Parse set a new benchmark for scalability of single cell experiments with the release of Evercode™ WT Mega, the industry’s highest throughput kit, enabling researchers to push the boundaries of their experimental designs. With the release of Evercode WT Penta, Parse continues to redefine the limits of single cell research. Penta is the only technology offering fixation and truly unbiased discovery of novel gene expr

Celerion Expands UK Phase 1 Clinical Research Operations With New Agreement to Relocate to Queen’s University Belfast’s iREACH Health – Clinical Research Innovation Center19.2.2025 14:00:00 CET | Press release

Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health. This state-of-the-art clinical research center, led by Queen’s University Belfast, in partnership with the Belfast Health and Social Care Trust, is set to become a cornerstone of Northern Ireland’s life sciences innovation ecosystem upon its early 2027 completion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219467591/en/ Set to complete in 2027, the state-of-the-art iREACH Health clinical research center is set to become a cornerstone of Northern Ireland's life sciences landscape. As part of this development, Celerion will relocate its U.K. Phase 1 clinical research operations to the facility, positioning it at the forefront of clinical research innovation. (Photo: Business Wire) Celerion’s Belfast clinic has a history of clinical research excellence spannin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye